Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 262 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
warfarin, placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HZN-825, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • Clearwater, Florida + 18 more
Completed Not applicable Interventional Results available

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968
Conditions
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions
Surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
81
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
Conditions
Pulmonary Fibrosis
Interventions
A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lakewood, Colorado • Reno, Nevada • Winston-Salem, North Carolina + 1 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Supplemental Oxygen in Pulmonary Fibrosis

NCT01961362
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Retrospective observational study- no intervention to occur.
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
Interventions
Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Brisbane, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SUPPORT, Currently Available Printed Material
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
IPF
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ACT-064992 (macitentan), Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Conditions
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions
Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Thalidomide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ORJ-001, Placebo
Drug · Other
Lead sponsor
Oorja Bio, Inc.
Industry
Eligibility
40 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Birmingham, Alabama • Doral, Florida • DuBois, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 3 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo, BI 3810477
Other · Biological
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Tucson, Arizona • Newport Beach, California • Palo Alto, California + 10 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

NCT03928847
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Epigallocatechin-3-gallate (EGCG)
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California